Vanda Pharmaceuticals Inc.
VNDA US9216591084
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 15% | -55% | -43% | 6% | 1% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Polymeropoulos Mihael Hristos CEO |
4.15 USD |
10,000 Bought |
41,500 USD |
07/08/2025 | 07/08/2025 |
| Mitchell Stephen Ray |
4.59 USD |
7,000 Sold |
32,130 USD |
13/06/2025 | 13/06/2025 |
| Mitchell Stephen Ray |
4.59 USD |
7,000 Sold |
32,130 USD |
13/06/2025 | 13/06/2025 |
| Polymeropoulos Mihael Hristos CEO |
4.40 USD |
9,519 Bought |
41,884 USD |
21/05/2025 | 21/05/2025 |
| Polymeropoulos Mihael Hristos CEO |
4.40 USD |
9,519 Bought |
41,884 USD |
21/05/2025 | 21/05/2025 |
| Polymeropoulos Mihael Hristos CEO |
4.39 USD |
481 Bought |
2,112 USD |
21/05/2025 | 21/05/2025 |
| Polymeropoulos Mihael Hristos CEO |
4.22 USD |
20,000 Bought |
84,472 USD |
16/05/2025 | 16/05/2025 |
| Polymeropoulos Mihael Hristos CEO |
5.01 USD |
5,000 Bought |
25,050 USD |
06/03/2025 | 06/03/2025 |
| Polymeropoulos Mihael Hristos CEO |
5.02 USD |
5,000 Bought |
25,100 USD |
06/03/2025 | 06/03/2025 |
| Polymeropoulos Mihael Hristos CEO |
5.03 USD |
5,000 Bought |
25,150 USD |
05/03/2025 | 05/03/2025 |